Catalyst Pharmaceuticals announces board election results and director O'Keeffe retirement at annual meeting

CATALYST PHARMACEUTICALS, INC.

Richard J. Daly, McEnany, Denkhaus, Harper, Thompson, Tierney elected to board; O'Keeffe retired after 20+ years, no disagreement.
Shareholders approved amendment to 2018 Stock Incentive Plan (85.4M for, 4.0M against).
Advisory vote on 2024 executive compensation passed (82.7M for, 6.5M against).
Grant Thornton LLP ratified as independent auditor for FY2025 (99.9M for, 1.2M against).

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Charles B. O'Keeffe

Director

CPRX · CATALYST PHARMACEUTICALS, INC.

Effective: 2025-05-20
Filed: May 23, 2025, 7:59 PM ET

As previously reported, Charles B. O’Keeffe, an independent member of the Board, did not stand for re-election at the Annual Meeting.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles B. O'Keeffe departed as Director at CATALYST PHARMACEUTICALS, INC..

Action: did not stand for re-election
Role: Director

Exact text from the filing

As previously reported, Charles B. O’Keeffe, an independent member of the Board, did not stand for re-election at the Annual Meeting.

View on SEC.gov

CATALYST PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-125872

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.